Precision treatment for salivary gland cancer
Part of Cancer, Mouth & dental clinical trials.
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with salivary gland cancer (confirmed by a biopsy).
- You are 18 years or older.
- Your daily activity level is fairly good (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans.
- You do not have serious heart, lung, liver, or kidney problems, or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for advanced salivary gland cancer that has spread or cannot be removed with surgery. The drugs may block hormones and slow cancer growth, potentially helping people whose tumors have specific markers.
This trial tests a new drug, Rezvilutamide, combined with standard hormone therapy for people with a rare and aggressive type of salivary gland cancer that has a high risk of coming back. The treatment aims to reduce the chance of cancer returning after surgery.
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
This trial tests an immunotherapy drug (toripalimab) with chemotherapy before surgery for salivary gland cancer. It aims to shrink the tumor to make surgery more effective.
This trial tests a combination of a targeted antibody-drug and focused radiation for people with advanced or recurrent salivary gland cancer that has spread. It aims to see if this treatment can help control the disease when standard treatments have stopped working.
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Hear when a new Precision Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.